Incitive aims to become a leader in the development of anti-inflammatory and immunosuppressent drugs. The business focus is to become a sustainable Life Science company by in-licensing technology and lead compounds at the discovery stage, taking them through preclinical studies to create significant added value, and partnering with large pharmaceutical or biotechnology companies for the clinical phase.

Incitive’s current pipeline of products are novel and based on over ten years of international peer-reviewed research. The lead products include small molecule drugs and protein drugs, all aimed to treat major indications such as organ transplantation and autoimmune diseases – large markets of substantially unmet clinical needs. The mix of scientific excellence, commercial expertise, access to top research facilities and a solid pipeline, puts Incitive in a favourable position in the market place.